Genkyotex: Disclosure of the total number of voting rights and shares pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority

(AMF – Autorité des Marchés Financiers)

ARCHAMPS, France & GENEVA--(BUSINESS WIRE)--Regulatory News:

Genkyotex (Paris:GKTX) (Brussels:GKTX):

Genkyotex shares ISIN code FR00011790542 – Euronext Paris & Brussels
Date	Number of shares making up the share capital	Number of voting rights
August 31^st, 2017	77,850,006	Theoretical number of voting rights^(1): 77,850,006
		Number of voting rights exercisable at a shareholders’ meeting^(2): 77,791,173

(1) In accordance with Article 223-111 of the AMF’s General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.
(2) Less shares stripped of voting rights.

About Genkyotex

Genkyotex is the leading biopharmaceutical company in NOX therapies. Listed on the Euronext Paris and Euronext Brussels markets, Genkyotex is established in France and, via its GenKyoTex Suisse SA subsidiary, in Switzerland. A leader in NOX therapies, its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.

Genkyotex’s platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor entered a phase II clinical trial in primary biliary cholangitis (PBC, a fibrotic orphan disease) in the second quarter of 2017. This product candidate may also be active in other fibrotic indications. Its second product candidate, GKT771, is a NOX1 inhibitor targeting multiple pathways in angiogenesis, pain processing, and inflammation, and should enter a phase I clinical study at the end of 2017.

Genkyotex also has a versatile platform well-suited to the development of various immunotherapies (Vaxiclase). A partnership covering the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Ltd (Serum Institute), the world’s largest producer of vaccine doses, for the development by Serum Institute of cellular multivalent combination vaccines against a variety of infectious diseases. This partnership could generate up to $57 million in future revenues for Genkyotex, before royalties on sales.

For further information, please go to www.genkyotex.com